read
great
interest
articl
khan
et
al
report
result
pilot
clinic
trial
administr
recombin
angiotensinconvert
enzym
patient
acut
respiratori
distress
syndrom
ard
current
research
focus
involv
system
ra
pathogenesi
clinic
outcom
ard
particular
evalu
angiotensinconvert
enzym
ace
angiotensin
ii
ang
ii
ang
ii
receptor
type
axi
counterpart
receptor
pathway
potenti
therapeut
target
given
lack
effect
pharmacolog
ard
treatment
clinic
trial
explor
new
therapeut
strategi
like
khan
et
al
essenti
associ
ace
activ
ard
outcom
far
linear
multipl
factor
like
heterogen
ard
variabl
ra
activ
patient
subgroup
could
implic
complex
interplay
even
though
increas
level
ace
ang
ii
detect
patient
ard
pathophysiolog
role
ra
ard
develop
remain
unclear
addit
factor
exampl
variabl
substrat
ace
apart
ang
name
bradykinin
apelin
protect
effect
lung
injuri
ang
ii
receptor
type
exert
effect
via
receptor
via
ang
ii
receptor
type
could
implic
encourag
data
anim
model
posit
effect
ard
respect
data
involv
human
insuffici
studi
higher
ace
level
associ
oxygen
index
even
though
dd
genotyp
relat
higher
serum
ace
level
seem
correl
ard
prognosi
zambelli
et
al
show
improv
arteri
oxygen
although
clinic
relev
experiment
ard
model
administr
angiotensin
differ
surviv
pulmonari
mechan
khan
et
al
studi
administr
recombin
ard
patient
decreas
ang
ii
level
without
caus
hypotens
worsen
respiratori
mechan
khanna
et
al
demonstr
ang
ii
administr
patient
vasodilatori
shock
increas
blood
pressur
without
rais
risk
ard
appar
variabl
often
conflict
data
current
literatur
complex
associ
ra
ard
warrant
conduct
addit
clinic
trial
elucid
pathophysiolog
background
evalu
potenti
new
treatment
